News Search Results
Feb 25, 2026, 08:30 ET Halozyme to Participate in Upcoming Investor Conferences
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Feb 25, 2026, 08:07 ET P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments
pathway from early diagnosis to accelerated orphan therapy development.Supported by a world-class consortium of leading biopharma companies, biotechnology innovators, patient advocacy groups, and globally recognized academic and clinical institutions, BeginNGS further strengthens P4ML's position as
More news about: Orphan Therapeutics Accelerator
Feb 25, 2026, 08:00 ET Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151
increasingly competitive DPP1 inhibitor landscape."About Melodia Therapeutics AGMelodia Therapeutics AG is a clinical-stage biotechnology company based in Basel, Switzerland, focused on developing innovative therapies targeting neutrophil-driven inflammatory diseases.About
More news about: Melodia Therapeutics AG
Feb 25, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer
announced the appointment of Bob Purcell as Chief Communications Officer. With 25 years of experience in corporate and product communications for biotechnology, pharmaceuticals, diagnostics, and healthcare technology companies, Purcell will support PICI's efforts to drive innovation and collaboration in
More news about: Parker Institute for Cancer Immunotherapy
Feb 25, 2026, 08:00 ET Evogene Releases CEO Letter to Shareholders
operate across the full range of collaboration models.In human health, we are advancing multiple partnered drug discovery programs with biotechnology companies and academic institutions. Throughout 2025 and early 2026, ChemPass AI™ discovered development-candidate predictions that have progressed
More news about: Evogene
Feb 25, 2026, 07:05 ET REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
VALENCIA, Spain, Feb. 25, 2026 /PRNewswire/ -- Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the publication of a peer-reviewed research article entitled
More news about: ARTHEx Biotech
Feb 24, 2026, 18:52 ET QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm
with an attorney.UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 24, 2026, 18:00 ET Nektar Therapeutics to Participate in Two Investor Conferences in March
conferences, please reach out to your respective representative.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 24, 2026, 16:01 ET AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 24, 2026, 13:09 ET Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals
Feb 24, 2026, 10:08 ET Cellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing
continuity."The collaboration will support a broad range of applications, including investigational cell therapies and platform technologies across biotechnology, pharmaceutical, and government-sponsored programs. Both companies will continue operating independently while collaborating to support shared clients.About
More news about: Cellipont Bioservices
Feb 24, 2026, 10:00 ET Particles for Humanity Announces Publication Demonstrating Breakthrough in Vitamin A Stability for Food Fortification
CAMBRIDGE, Mass., Feb. 24, 2026 /PRNewswire/ -- Particles for Humanity, a mission-driven biotechnology company developing nutrition technologies for low- and middle-income countries, today announced the publication of new data in
More news about: Particles for Humanity
Feb 24, 2026, 10:00 ET Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1
patients, the ketogenic diet can be challenging to maintain long term.About Bloom ScienceBloom Science is a clinical-stage biotechnology company developing new therapies for neurological disorders and metabolic diseases, including obesity. Rooted in gut-brain axis biology and microbiome
More news about: Bloom Science, Inc.
Feb 24, 2026, 09:35 ET Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
https://www.financialnewsmedia.com/news-help/Latest Biotech Drugs Attracting Interest may also include:Compass Pathways plc (NASDAQ: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation,
More news about: Market News Updates
Feb 24, 2026, 09:00 ET Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the appointment of Blake Arnold, CFA, as Chief Business
More news about: Kenai Therapeutics/BIOCOM
Feb 24, 2026, 09:00 ET BioMarin to Participate in Four Upcoming Investor Conferences in March
Company's website for a limited time following the conferences.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Feb 24, 2026, 09:00 ET Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market
care, orthobiologics, and regenerative medicine, is pleased to announce a transformative investment and strategic partnership with Jellagen Ltd, the UK-based biotechnology innovator pioneering Collagen Type Zero: a next-generation, jellyfish-derived, sustainable biomaterial.
More news about: Royal Biologics
Feb 24, 2026, 09:00 ET Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
equity restructuring. The shares previously held by Haier Financial Holdings have been formally acquired by existing shareholder Shanghai Liferiver Biotechnology Co., Ltd. ("Liferiver Biotech") and new strategic investor Shenzhen Yanghe Biomedicine Industry Investment Co., Ltd. ("Yanghe Investment").
More news about: Sanyou Bio
Feb 24, 2026, 09:00 ET Accelerated Engineering Software and Certified Composite Production Capturing Share of $100B+ Aerospace Market
the development of next-generation biotechnology and materials science under the Functional Responsive Experimentation for Systems and Humans (FRESH) program at Wright Patterson Air Force Base in Dayton, Ohio.Under Task Order 0003 (TO-03), titled "Biotechnology and Biomaterials and Polymers and
More news about: Market News Updates
Feb 24, 2026, 08:50 ET Draper and Partners Awarded ARPA-H Funding to Develop New In Silico Models of Human Physiology for Drug Development
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
technologiesSAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Therna Biosciences, a biotechnology company pioneering programmable RNA medicines, today announced the appointment of Devyn Smith, Ph.D., as an independent member of its Board of Directors,
More news about: Therna Biosciences
Feb 24, 2026, 08:05 ET Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
replay for 90 days after the call via the Rigel website.About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Feb 24, 2026, 08:00 ET K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026
K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet medical need, today announced data from its Phase 1 clinical trial of KTX-2001
More news about: K36 Therapeutics
Feb 24, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Tax Certificate Transfer Program (NOL Program)The Technology Business Tax Certificate Transfer Program enables approved technology and biotechnology businesses with net operating losses to sell their unused net operating loss carryover (NOL) and unused research and development tax credits (R&D
More news about: Citius Pharmaceuticals, Inc.